Business
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform
AUBAGNE, France & BRATISLAVA, Slovakia, July 09, 2025--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic mRNA.
About this update from Sartorius Stedim Biotech Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/e23106a40ab1100bcb99be8824113ddc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.tG6B_rSxNHygWUyoXTTEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e23106a40ab1100bcb99be8824113ddc","width":480,"height":270}},"lazy":false},{"type":"text","content":"AUBAGNE, France & BRATISLAVA, Slovakia, July 09, 2025--(BUSINESS WIRE)--Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, and Sensible Biotechnologies, a pioneer in cell-based design and manufacturing of mRNA therapeutics, have signed a Memorandum of Understanding (MoU). The two companies will jointly advance the industrialization and scale-up of Sensible’s first-in-class cell-based platform for the design, optimization, and manufacturing of high-quality mRNA. The collaboration aims to enable clinical-grade production of cell-based mRNA by 2026 and unlock the next generation of mRNA medicines.","length":647,"tagName":"p"},{"type":"text","content":"As part of the agreement, Sartorius Stedim Biotech has already provided significant support through advanced equipment and consumables. The partnership will extend to process development, closed-system facility design, and technical support to rapidly establish Sensible’s GMP-compliant mRNA production capabilities. These activities will enable Sensible to expand production from Slovakia to the US, UK, and broader Europe.","length":424,"tagName":"p"},{"type":"text","content":""Sartorius Stedim Biotech has played a vital role in enabling global biologics manufacturing - from vaccines to gene therapies - and we are honoured to work with them to build the industrial backbone to unlock the next generation of mRNA therapeutics," said Miroslav Gašpárek, Sensible’s CEO and co-founder. "This partnership is a critical milestone in Sensible’s journey to deliver first-in-class clinical-grade mRNA manufactured in living cells with unprecedented purity and performance, which is required for therapeutic applications of mRNA."","length":566,"tagName":"p"},{"type":"text","content":""We are excited to support Sensible in scaling a disru...